Department of Chemistry, National Institute of Technology-Durgapur, Durgapur, West Bengal 713209, India.
J Mol Graph Model. 2013 Jul;44:70-80. doi: 10.1016/j.jmgm.2013.04.010. Epub 2013 May 14.
Transthyretin (TTR) is a protein whose aggregation and deposition causes amyloid diseases in human beings. Amyloid fibril formation is prevented by binding of thyroxin (T4) or its analogs to TTR. The MD simulation study of several solvated X-ray structures of apo and holo TTR has indicated the role of a conserved water molecule and its interaction with T4 binding residues Ser117 and Thr119. Geometrical and electronic consequences of those interactions have been exploited to design a series of thyroxin analogs (Mod1-4) by modifying 5' or 3' or both the iodine atoms of thyroxin. Binding energy of the designed ligands has been calculated by docking the molecules in tetrameric structure of the protein. Theoretically investigated pharmacological parameters along with the binding energy data indicate the potentiality of 3',5'-diacetyl-3,5-dichloro-l-thyronine (Mod4) to act as a better inhibitor for TTR-related amyloid diseases.
转甲状腺素蛋白(TTR)是一种蛋白质,其聚集和沉积会导致人类的淀粉样变性疾病。甲状腺素(T4)或其类似物与 TTR 的结合可防止淀粉样纤维的形成。对几种溶剂化的 apo 和 holo TTR 的 X 射线结构的 MD 模拟研究表明,保守水分子及其与 T4 结合残基 Ser117 和 Thr119 的相互作用起作用。通过修饰甲状腺素的 5'或 3'或两者的碘原子,利用这些相互作用的几何和电子后果设计了一系列甲状腺素类似物(Mod1-4)。通过将分子对接在蛋白质的四聚体结构中,计算了设计配体的结合能。理论研究的药理学参数以及结合能数据表明,3',5'-二乙酰基-3,5-二氯-l-甲状腺素(Mod4)有可能成为治疗 TTR 相关淀粉样变性疾病的更好抑制剂。